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OBJECTIVE: To evaluate the effects of 2 different doses of exogenous surfactant on pulmonary mechanics and on the
regularity of pulmonary parenchyma inflation in newborn rabbits.
METHOD: Newborn rabbits were submitted to tracheostomy and randomized into 4 study groups: the Control group
did not receive any material inside the trachea; the MEC group was instilled with meconium, without surfactant treatment;
the S100 and S200 groups were instilled with meconium and were treated with 100 and 200 mg/kg of exogenous surfactant
(produced by Instituto Butantan) respectively. Animals from the 4 groups were mechanically ventilated during a 25-minute
period. Dynamic compliance, ventilatory pressure, tidal volume, and maximum lung volume (P-V curve) were evaluated.
Histological analysis was conducted using the mean linear intercept (Lm), and the lung tissue distortion index (SDI) was
derived from the standard deviation of the means of the Lm. One-way analysis of variance was used with a = 0.05.
RESULTS: After 25 minutes of ventilation, dynamic compliance (mL/cm H2O · kg) was 0.87 ± 0.07 (Control); 0.49 ±
0.04 (MEC*); 0.67 ± 0.06 (S100); and 0.67 ± 0.08 (S200), and ventilatory pressure (cm H2O) was 9.0 ± 0.9 (Control); 16.5 ±
1.7 (MEC*); 12.4 ± 1.1 (S100); and 12.1 ± 1.5 (S200). Both treated groups had lower Lm values and more homogeneity in
the lung parenchyma compared to the MEC group: SDI = 7.5 ± 1.9 (Control); 11.3 ± 2.5 (MEC*), 5.8 ± 1.9 (S100); and 6.7
± 1.7 (S200) (*P < 0.05 versus all the other groups).
CONCLUSIONS: Animals treated with surfactant showed significant improvement in pulmonary mechanics and more
regularity of the lung parenchyma in comparison to untreated animals. There was no difference in results after treatment with
either of the doses used.
KEY WORDS: Meconium. Surfactant inactivation; Neonate; Newborn animals; Pulmonary mechanics.
Meconium aspiration syndrome
(MAS) is characterized by respiratory
distress in term newborns (NB) that ex-
perience intra-uterine or immediately
postdelivery meconium elimination,
together with specific radiological
findings. Despite the several available
therapeutic proposals, MAS still re-
mains an important cause of mortality
in this group of patients, with rates that
vary from 4% to 37% (median of
12%).2-4
The aspirated meconium initially
causes airway obstruction and an in-
crease in pulmonary resistance. Subse-
quently, the presence of this substance
inside the alveoli provokes an intense
inflammatory response, with a poly-
morphonuclear and macrophage
leukocyte accumulation, pulmonary
edema, and chemical mediator release,
causing a chemical pneumonitis.3,5 Ad-
ditionally, several experimental stud-
ies have demonstrated that the pres-
ence of meconium in the distal airways
may cause an abnormality in sur-
factant function as a result of its inhi-
3185.p65 13/07/04, 15:20104
105
REV. HOSP. CLÍN. FAC. MED. S. PAULO 59(3):104-112, 2004 Different doses of exogenous surfactant
Lyra JC et al.
bition or alteration of its composition,
leading to reduction in lung compli-
ance and functional residual capacity,
atelectasis, and hypoxia. Despite these
findings, the precise mechanism of ac-
tion has not been completely clari-
fied.6-9
According to in vitro and in vivo
research models, this inhibitory effect
on surfactant function is due to altera-
tions in the surfactant monolayer, the
properties of which are modified as a
consequence of the infiltration of fatty
acid molecules into its interior or as a
consequence of lysophosphatidyl-
choline production from the phos-
pholipid of meconium. This infiltra-
tion results in perforations in the cel-
lular membrane of the type II
pneumocytes, causing asymmetry of
the monolayer.10 The reduction of sur-
factant protein (SP) -A and SP-B lev-
els and a decreased number of phos-
pholipid when the meconium is added
to the surfactant has been also demon-
strated7. The presence of hemorrhage,
edema, inflammatory cells, and chemi-
cal mediators inside the alveolus also
contributes to the inactivation of the
surfactant observed in MAS.11-13
During the 1990s, several experi-
mental studies demonstrated the ben-
efits of rescue therapy with exogenous
surfactant in the treatment of MAS in
animal models, with a significant im-
provement of dynamic pulmonary
compliance and ventilatory pressure,
decreased need for oxygen, better pul-
monary aeration, decreased formation
of hyaline membranes, decreased intra-
alveolar edema, and reduced neu-
trophil influx into the intra-alveolar
spaces after treatment with exogenous
surfactant.10,13,14,15,16
On the other hand, a number of
controlled clinical studies evaluating
the use of exogenous surfactant for
MAS treatment, most involving a
small number of patients, produced
conflicting results.14,17-19
Considering the complex patho-
physiology involved with MAS and
the divergence between experimental
and clinical results, doubts remain re-
garding the doses, the administration
time, interval, and type of surfactant to
be used with rescue therapy.
The purpose of the present study
was to evaluate the effects of 2 differ-
ent doses of a low-cost surfactant pro-
duced with Brazilian technology on
the respiratory mechanics and mor-
phological pulmonary pattern of new-
born rabbits with MAS.
MATERIALS AND METHOD
Meconium preparation
MAS was induced in newborn rab-
bits through endotracheal administra-
tion of human meconium, at a 65 mg/
mL concentration, in a 6 mL/kg dose,
following the techniques of experi-
mental models that are described in the
literature.13,16
Meconium was collected on the
first day of life from normal term
newborns where there was no history of
maternal drug exposure and no urine
contamination. The samples were
packed into plastic collectors and kept
unfrozen at 3°C until acceptance by the
investigator. Initially, the meconium was
diluted in distilled water to a concen-
tration of 25 mg/mL and was filtered to
remove particles with a diameter
greater than 3 mm, aiming at eliminat-
ing the likely effect of obstructing the
airways. Afterwards, the material was
lyophilized. For meconium administra-
tion to the animals, the lyophilized
meconium was reconstituted with a
physiological saline solution to a 65
mg/mL concentration.13,16,20
Surfactant preparation
The surfactant used in this study
was produced and supplied by
Instituto Butantan in São Paulo at a 25
mg lipid/mL concentration. The sur-
factant was obtained by maceration of
porcine lung and was composed of
phospholipids (phosphatidylcholine,
phosphatidylethanolamine, phos-
phatidylglycerol, phosphatidylino-
sitol, phosphatidylserine, and sphingo-
myelin) and 2 proteins (SP-B and SP-
C).21 The product was kept unfrozen at
3°C until the time of administration;
all samples were obtained from the
same production lot.
This surfactant had been tested and
proven effective in a previous study
that used the experimental model of
premature newborn rabbits with respi-
ratory distress syndrome.22
Experimental animals
Birth and ventilation beginning
Term newborn rabbits from New
Zealand White breed were used. They
were obtained through a cesarean at 30
days gestation. Initially, the pregnant
rabbits were sedated with an intramus-
cular application of ketamine and
acepromazine solution (10 mg/kg and
0.1 mg/kg), followed by spinal
anesthesia with 2 mL of a 1:1 (vol:vol)
solution of 2% lidocaine and 0.5%
bupivacaine. After the laparotomy and
hysterotomy over a thermal mattress,
the newborn rabbits were delivered,
and the membranes and the placentas
were removed.
After being dried and weighed,
each newborn rabbit was anesthetized
with an intraperitoneal administration
of ketamine–acepromazine (10 mg/
kg–0.1 mg/kg) and submitted to tra-
cheostomy with a metal cannula (in-
ternal diameter of 1 mm). Animals that
weighed under 35 g were excluded
from the study. Before the beginning
of ventilation, endotracheal adminis-
tration of meconium (65 mg/mL), in a
6 mL/kg dose, and manual ventilation
with a self-inflating bag for about 10
seconds were performed. Afterwards,
the animals received pancuronium
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Table 1 - Number of animals and weight (mean ± sd) for each group.
Group Number of animals Weight (g)
Control  9  40.3 ± 3.9 *
MEC  9  42.7 ± 6.5
S100  9  37.3 ± 2.3
S200  13  43.3 ± 6.7
P = .069 vs all the other groups
through an intraperitoneal route (20
µg) so there would be no spontaneous
respiration. The mechanical respira-
tion was started (INTER 3 â —
Intermed-São Paulo) using a respira-
tory rate (RR) of 60 cycles/min with
an inspired oxygen concentration
(FiO2) of 1.0 and a peak inspiratory
pressure (PIP) necessary to acquire a
tidal volume of 8 mL/kg and positive
end-expiratory pressure (PEEP) of 3 cm
H2O. Controlled assisted ventilation
was continued for a 25-minute period.
The animals were randomized into
4 groups as follows: having no meco-
nium aspiration (Control); having
meconium aspiration, without exog-
enous surfactant treatment (MEC);
having meconium aspiration with 100
mg/kg surfactant treatment (S100);
having meconium aspiration with 200
mg/kg surfactant treatment (S200). All
treatments were administered in the
10th minute of ventilation.
After the beginning of the ventila-
tion, tidal volume (VT), dynamic com-
pliance (DC), and ventilatory pressure
(VP) at 5, 10, 15, 20, and 25 minutes
were determined. The data were gath-
ered with the help of a pneumo-
tacograph (Hans Rudolph Inc.®) at-
tached to a pressure transducer
(Validyne®), and they were analyzed
with the help of specific software (Lab
View Data Aquisition® - National Instru-
ments). Ventilatory pressure was consid-
ered to be the difference between the PIP
and the PEEP, and dynamic compliance
(mL/cm H2O · kg) was calculated
through the division of VT (mL/kg) by
VP (cm H2O). Adjustment of the PIP was
performed as necessary in order to main-
tain a target VT of 8 mL/kg at 30 sec-
onds before every measurement.
The animals that did not present a
reduction of their lung compliance
values equal to or greater than 30%
compared with the Control group and
those that presented signs of pneumot-
horax at any time during the study
were excluded.
Animal sacrifice and lung manipula-
tion
After 25 minutes of ventilation, the
animals were deeply sedated with intra-
peritoneal sodium pentobarbital (25
mg/kg), followed by tracheal clamping
for 5 minutes to measure the pulmonary
pressure-volume curve (P-V curve).
After the sacrifice of the animals with
an intrathecal injection of 0.5 ml of 2%
lidocaine, the P-V curve measurement
was performed, measuring the lung vol-
ume 30 seconds after insufflation, at in-
crements of 5 cm H2O until a maximum
pressure of 30 cm H2O was achieved, fol-
lowed by the deflation of the lung at 5
cm H2O decreased to 0 cm H2O.
After the P-V curve was measured,
the lungs were inflated to 30 cm H2O
pressure for 1 minute, followed by a
decrease of the pressure to 10 cm H2O
and tracheal clamping. The animals
were dissected, with removal of the
lung and heart as a unit. The pulmo-
nary tissue for histology was obtained
using a standardized procedure for de-
termining a representative area, as de-
termined from a pilot study, selecting
tissue slices (5 mm thickness) from
pulmonary regions with better macro-
scopic evidence of the presence of
meconium. The fragments were fixed
in a 10% formalin solution for a mini-
mum period of 24 hours. The tissue
was then processed in paraffin and
stained with hematoxylin and eosin.
Histopathology
The histopathology was done us-
ing optical microscopy, aiming at
studying areas of atelectasis or pulmo-
nary hyperinsufflation. For this, the
number of alveolar intercepts was de-
termined through a grid with 50 lines
and 100 points with a known size,
where 10 fields per slide under 200x
magnification were counted. For com-
parison between the groups, the mean
linear intercept (Lm) from the number
of intercepts per field and the lung tis-
sue distortion index (SDI) were deter-
mined. The Lm was calculated from the
relationship between the length of the
lines and the number of intercepts
(crossing of the lines with the alveo-
lar septum), and the SDI was deter-
mined from the standard deviation of
the means of Lm in each group.
Statistical analysis
The comparison of the means be-
tween the groups was done by 2-way
analysis of variance with the Student-
Newman-Keuls test as the discriminatory
posttest, adopting a significance level of
5%. When the data did not present the
prerequisite of a normal distribution and
the similar variances, the Kruskal-Wallis
1-way analysis of rank test was used as
a test for nonparametric data. The com-
parison among proportions was done us-
ing the chi-square test.
RESULTS
Twenty females were used, with a
total of 50 neonates. There were 4 ani-
mals that were excluded due to pneu-
mothorax, 2 animals with a birth
weight under 35 g, and 4 that did not
present a decline in the lung compli-
ance greater than 30% in relation to the
Control group. The number of animals
and the mean weight in each group are
summarized on table 1.
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Figure 2 - Values of dynamic lung compliance (DC). After the administration of surfactant (100
or 200 mg/kg) with 10 minutes of ventilation, there was a significant improvement of both
treated groups in relation to the MEC group, independent of the dose used.
Figure 1 - Values of tidal volume (VT) of the 4 groups during the 25 minutes of ventilation. The
VT varied from 7.9 to 8.2 mL/kg, having no differences among the 4 groups.
Respiratory mechanics
Figures 1, 2, and 3 show the ani-
mals’ behavior in the first 25 minutes
of mechanical ventilation regarding
the tidal volume (VT), dynamic com-
pliance, and ventilatory pressure. The
VT remained stable (varying from 7.9
to 8.2 mL/kg) during the entire venti-
lation period, and there were no differ-
ences among the 4 groups (Figure 1).
The 3 groups that received meco-
nium through an endotracheal route
had a decrease in the dynamic compli-
ance values greater than or equal to
30% compared with the animals from
the Control group. The animals that
were treated with exogenous surfactant
showed a significant improvement of
dynamic compliance compared with
the MEC group, whereas there were no
differences regarding the surfactant
dose used (Figure 2). Similar results
were found regarding the ventilatory
pressure, with higher pressures in ani-
mals from the MEC group (Figure 3).
The P-V curves are shown in Fig-
ure 4. The untreated animals (MEC
group) needed a higher pressure to
start the pulmonary insufflation com-
pared with the animals from the S200
group and achieved a lower volume
with a maximum pressure of 30 cm
H2O when compared with the control
and treated groups. In the pulmonary
deflation phase at pressures of 20 and
25 cm H2O, the S100 and S200 groups
had better alveolar stability, or rather
a smaller tendency to collapse com-
pared with the MEC group. Neverthe-
less, at a pressure of 5 cm H2O, the
MEC group had a higher volume than
the groups that were treated with sur-
factant. Differences between the S100
and S200 groups were not observed.
Histopathology
Histology was performed on a
minimum sample of 6 animals in each
group. The lungs of the animals from
the MEC group presented a pattern of
heterogeneous pulmonary aeration
with the focus of atelectasis distributed
between normal and hyperinsufflated
areas, while both groups that were
treated showed a more homogeneous
pattern.
 Figure 5 shows the mean linear in-
tercept (Lm) and the lung tissue dis-
tortion index (SDI) of each group. The
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Figure 3 - Values of ventilatory pressure (VP). After the administration of surfactant (100 or
200 mg/kg) with 10 minutes of ventilation, there was a significant decrease of the VP values
necessary for maintaining the target VT for the 2 treated groups compared with the MEC group,
independent of the dose used.
Figure 4 - Values of the pulmonary volume-pressure (P-V) curve. The animals of the MEC
group needed a more elevated pressure to initiate the pulmonary insufflation compared with
the Control and S200 groups. Under the maximum pressure of 30 cm H2O, the animals of the
Control, S100, and S200 groups had a greater pulmonary volume, maintaining this standard
during the entire deflation phase until a pressure of 20 cm H2O was reached. There was no
difference between the 2 groups treated with exogenous surfactant.
Lm from the Control and MEC groups
were similar, and both had a statisti-
cally significant difference in relation
to the S100 and S200 groups.
Analyzing only the SDI, both treated
groups were similar to the Control
group, with these 3 groups differing
from the MEC group.
DISCUSSION
Several publications have demon-
strated the meconium-inactivating ef-
fect on surfactants7,12,20,23-25. However,
there are a small number of investiga-
tions that studied the effects of replace-
ment therapy using exogenous
surfactants in animal models with
MAS. The majority of these studies
were published by the same group of
researchers, which justifies the per-
formance of more experimental re-
search with this approach.15,16,26 Sun et
al.13 developed an animal model to
quantify, under well-defined experi-
mental conditions, the effects of meco-
nium aspiration on the pulmonary
function of term newborn rabbits and
later the effects of the treatment with
surfactant of rabbits with MAS.16 We
chose to reproduce this model because
the monitoring of the pulmonary me-
chanic proprieties is possible. Addi-
tionally, rabbits are low-cost small ani-
mals that are easy to handle and repro-
duce, with a large number of offspring
per brood.27
We followed the previously pub-
lished meconium administration and
preparation techniques in which the
meconium was initially diluted and fil-
tered, eliminating the larger particles
of 3 micrometers or more. This proce-
dure allowed the most homogeneous
distribution of meconium, avoided ob-
struction of airways, and restrained
main effect of the meconium to that of
surfactant inactivation.13,16 Since pre-
vious experiments had demonstrated
that there was no difference in the use
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Figure 5 - Values of the mean linear intercept (Lm) to the left and the lung tissue distortion
index (SDI) to the right. The groups that received surfactant (100 or 200 mg/kg) had lower
values of Lm and SDI, which denote a lower alveolar diameter and a more homogeneous
pulmonary expansion pattern for the treated groups compared with the MEC group.
of concentrations of 65 or 130 mg/mL
regarding decreases in the lung com-
pliance,13,16 we chose the lower con-
centration (65 mg/mL) because of its
greater ease of administration through
tracheal cannulae with reduced inter-
nal diameters. The meconium volume
that was used was the necessary one for
induction of MAS in adult rats with a
decrease of the lung compliance val-
ues greater than or equal to 30%,
which was determined as being from
4 to 6 mL/kg.26
There is not a standardization of
ventilatory parameters in the literature
to be used in animal models.27 Sun et
al.16 used in newborn rabbits a RR of
40 inspirations per minute, PEEP of 0,
FiO2 of 1.0, and a 1:1 relationship I:E;
adjusting the PIP every 15 minutes to
achieve a pre-established VT of 8 to 10
mL/kg. Subsequently, these authors
used the same RR and FiO2 parameters
in adult rats, but at this time, they fixed
the PIP and PEEP initially at 10 and 0
cm H2O with a subsequent increase to
28 and 5 cm H2O respectively, and
variations in the VT were observed;
they concluded that higher levels of
PIP are needed to assure a VT greater
than 6 mL/kg, which is essential for
the survival of the animals under these
conditions.13,26 In another study with
rats,15 a new manner of ventilation was
proposed to mimic clinical practice,
adjusting the ventilator parameters ac-
cording to the monitoring of the arte-
rial gases. We have based our study on
these studies and also on data from
clinical practice, fixing the VT at 8
mL/kg and making adjustments in the
PIP values as needed to assure homo-
geneous ventilation among all the
studied animals.
The ventilation time was fixed at
25 minutes, which was ample time for
the surfactant inactivation to oc-
cur.15,16,20,26 This fact has been con-
firmed by our results, where it was ob-
served that immediately after receiv-
ing meconium in the trachea, the ani-
mals had a decrease in lung compli-
ance with a higher necessity of
ventilatory pressure compared with
controls. Additionally, ventilation
time greater than 30 minutes is asso-
ciated with a high prevalence of pneu-
mothorax and an elevated mortality in
this animal model28.
Herting et al.25 compared the in-
hibitory effects of meconium on sev-
eral types of exogenous surfactants and
demonstrated that the several
surfactants react in a different way to
inhibition by meconium, depending
on the apoprotein type and concentra-
tion. In our experiment, we used a sur-
factant that was produced with a Bra-
zilian technology by Instituto
Butantan, the effectiveness of which
had already been demonstrated for
SDR treatment in premature rabbits.22
Additionally, a pilot study (unpub-
lished data) demonstrated that this sur-
factant, whenever administered to rab-
bits with MAS, behaves similarly to
CurosurfÒ, a preparation available on
the international market. The study of
the effectiveness of this surfactant is
part of a research line that is being de-
veloped in our laboratory.
The surfactant dose used in the ex-
periments varied between 100 to 200
mg/kg.13,15,16 Use of these dosages was
derived from knowledge that in MAS
an inactivation of the exogenous sur-
factant also occurs; therefore, the bet-
ter option would be the higher dose.
Sun et al. 26 treated rats with MAS with
a modified porcine surfactant at doses
of 100 and 200 mg/kg, and the best re-
sults were obtained with the higher
dose, however, in this experiment, tra-
cheal aspiration was performed at pre-
determined moments, which might
have caused misinterpretation of the
results, because of the possible sur-
factant removal during the aspiration
.
In our study, we opted for compar-
ing 2 doses (100 and 200 mg/kg),
since the initial hypothesis was that
the higher dose would be more effec-
tive and previous studies had not
analyzed this comparison. The inclu-
sion of the Control group allowed the
evaluation of the magnitude of the
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worsening of the respiratory mecha-
nism after the installation of MAS, as
well as the magnitude of the improve-
ment after treatment with exogenous
surfactant.
The 4 groups were ventilated in a
homogeneous manner as demonstrated
by the results of VT measurements,
which remained without differences
between the 4 groups during the en-
tire ventilation period.
The animals with MAS had signifi-
cant improvement in values of both
lung compliance and ventilatory pres-
sures after treatment with surfactant,
independent of the dose used, but they
did not attain the results of the Con-
trol group. Regarding pre-treatment
compared with final ventilation val-
ues, there was a mean increase of 56%
in the values of lung compliance and
a mean reduction of 35% of the P-V
values. Our results are in accord to
those of Sun et al.16 where the
posttreatment mean lung compliance
improvement was of 31% in the
groups of rabbits with MAS that had
received 200 mg/kg of surfactant when
compared with untreated animals. In a
following study, these same authors
used dosages of 100 and 200 mg/kg
for the treatment of MAS in adult rats
and concluded that there was an in-
crease of lung compliance as well as
an improvement in the PaO2 values of
both treated groups. Even though that
study was performed with a different
experimental model, the compliance
values after 30 minutes of ventilation
were comparable to those in our study
(0.67 ± 0.08 and 0.65 ± 0.15 mL/ cm
H2O · kg respectively). These effects
were only sustained in animals that re-
ceived the higher dose, a finding that
was observed at longer times of venti-
lation in that experiment, which was
extended to 210 minutes.26 The study
by Sun et al.15, also in adult rats with
MAS, compared the immediate and
delayed administration of surfactant at
a dose of 200 mg/kg. Their results
demonstrated that lower values of
ventilatory pressure were required for
the attainment of the target values for
PaO2, PaCO2 and pH for the treated
animals, independent of the time of
administration, compared with the
group without treatment. The results of
these last 2 studies suggest that the
beneficial effects for the treatment of
MAS occur with the use of high doses
of surfactant. However, in our study,
there was no difference between the 2
doses, but the sustained effect could
not be evaluated due to the ventila-
tion time of 25 minutes used.
In the evaluation of static lung
compliance from the P-V curve, we ob-
served that the beginning pulmonary
pressure was higher for the group with-
out treatment only in relation to the
group of animals that were treated with
200 mg/kg of surfactant. This
behavior remained during the entire
pulmonary insufflation phase. How-
ever, at the maximum pressure of 30
cm H2O and during the pulmonary de-
flation phase until reaching a pressure
of 20 cm H2O, both treated groups pre-
sented higher pulmonary volumes
than the untreated animals. Unexpect-
edly, we obtained a higher pulmonary
value in the MAS group at the defla-
tion pressure of 5 cm H2O, which may
be explained by a possible obstruction
mechanism caused by a greater
amount of viscous pulmonary liquid
present in this group, impeding the
exit of air. This effect may not have
been noticeable at the higher pres-
sures; it could only be observed low
pressures, since the surface tension of
this liquid is elevated because of the
surfactant deficiency, as occurs for ani-
mals models with respiratory distress
syndrome.29
The results of the pulmonary me-
chanics measurements were in accord
with the findings of the histopathology.
Histology revealed that the group of
treated animals had a lower mean Lm
and a greater homogeneity of the pul-
monary expansion pattern with fewer
areas of atelectasis and hyperin-
sufflation when compared with the
group without treatment, which was
demonstrated through the calculation
of the lung tissue distortion index.
This index detects changes in the tis-
sue morphology and is performed to
evaluate the atelectasis and hyperin-
sufflation pattern or the field-by-field
variation of alveolar size.30,31 Our re-
sults are comparable to the histologi-
cal findings by Sun et al.15,16,26, in
which surfactant treatment caused an
increase in the alveolar volume with
fewer areas of atelectasis, with a reduc-
tion of the lung tissue distortion index
after treatment with surfactant.
The present study has shown an
improvement of the lung compliance
following surfactant therapy for MAS
that is independent of the surfactant
dose used. Our results reinforce the
idea that the qualitative deficiency of
surfactant is an important event in
MAS physiopathology, arguing
favorably for surfactant replacement
therapy for newborns with this illness,
which might reduce the inherent risks
of mechanical ventilation by reducing
the required ventilatory pressure.
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RESUMO
S200, ambos com aspiração de mecô-
nio e tratados respectivamente com
100 e 200 mg/kg de surfactante exó-
geno (produzido e fornecido pelo Ins-
tituto Butantan). Os animais dos 4 gru-
pos foram ventilados por 25 minutos.
A mecânica pulmonar foi avaliada a
partir dos valores de complacência di-
nâmica, pressão ventilatória, volume-
corrente e volume
pulmonar máximo (curva P-V). A
análise histológica foi feita calculan-
do-se o diâmetro alveolar médio (Lm)
e o índice de distorção através do des-
vio padrão do Lm. Utilizou-se ANOVA
One Way com a = 0,05.
RESULTADOS: Após 25 minutos
de ventilação, os valores de complacên-
cia dinâmica (ml/cm H2O.kg) foram:
0,87± 0,07 (Controle); 0,49±0,04
(MEC*); 0,67±0,06 (S100) e 0,67±0,08
LYRA JC e col. Estudo dos efeitos de
diferentes doses de surfactante
exógeno para o tratamento da
síndrome de aspiração de mecônio
em coelhos recém-nascidos. Rev.
Hosp. Clín. Fac. Med. S. Paulo
58(3):104-112, 2004.
OBJETIVO: Avaliar os efeitos de
duas diferentes doses de surfactante
exógeno sobre a mecânica pulmonar e
sobre a regularidade da expansão do
parênquima pulmonar em coelhos re-
cém-nascidos.
MÉTODO: Coelhos recém-nasci-
dos foram traqueostomizados e rando-
mizados em quatro grupos de estudo:
grupo-Controle, sem aspiração de
mecônio; grupo MEC, com aspiração
de mecônio e sem tratamento com
surfactante exógeno; grupos S100 e
(S200) e de pressão ventilatória (cm
H2O): 9,0± 0,9 (Controle); 16,5±1,7
(MEC*); 12,4±1,1 (S100) e 12,1±1,5
(S200). Ambos os grupos tratados tive-
ram padrão de expansão do parênquima
mais homogêneo em relação aos ani-
mais não tratados: índice de distorção
de 7,5± 1,9 (Controle); 11,3±2,5
(MEC*); 5,8±1,9 (S100) e 6,7±1,7
(S200) (*p < 0,05 vs outros grupos).
CONCLUSÕES: Animais tratados
com surfactante mostraram melhora
significativa da mecânica pulmonar e
maior homogeneidade do padrão de
expansão pulmonar comparados ao
grupo não tratado. Não houve influên-
cia das doses de surfactante utilizadas.
UNITERMOS: Mecônio. Surfac-
tante exógeno. Recém-nascido. Mode-
lo animal. Mecânica pulmonar.
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